(Image courtesy of Akili Interactive)
March 29, 2021
Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment.
"These results increase the...
February 8, 2021
Boston Children’s Hospital spin-out Mightier is teaming up with Magellan Health to study how the former’s video-game like therapy can improve emotional regulation for children, thanks to a $2 million National Institute of Mental Health grant.
The pair will be launching a new study to evaluate the impact of Mightier’s biofeedback video game platform on improving behavior and in children with...
June 2, 2020
Braingaze, a digital therapeutic company out of Barcelona, Spain, is preparing to launch its ADHD therapy app on Android, iOS and Windows tablets.
The company isn’t new exactly, it was founded in 2013 and is a University of Barcelona spin-out. The Spanish startup has designed a video-game like ADHD therapy tool dubbed BGaze Bird, which includes a selfie camera that lets a clinician oversee the...
February 24, 2020
A full transcript of STARS-ADHD — the pivotal trial of Akili Interactive’s video game-like pediatric attention deficit treatment — has been published in The Lancet Digital Health journal, providing onlookers a clear view of data fueling the digital therapeutic company’s pending FDA submission.
The writeup echoes topline findings first unveiled by the company in December 2017: compared to a...
January 15, 2020
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error.
Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication.
Called the ...
November 14, 2019
A personalized, interactive brain-training game will soon be helping children with Attention Deficit Hyperactivity Disorder (ADHD) improve their attention span. The advantage of this technology is that that children with ADHD can participate in this program from home. A pilot run for the home-based program will be launched for 20 children, aged 6-12 years, who are currently receiving treatment...
August 20, 2019
ATENTIV, maker of a video game-based intervention for ADHD, has partnered with Children’s Specialized Hospital’s Center for Discovery, Innovation and Development (CDID) to explore a novel care model blending both behavioral and primary care.
Of particular note, ATENTIV and CDID, part of the RWJBarnabas Health system in New Jersey, will be investigating how to deploy the therapy, called...
March 7, 2019
Boston-based Akili Interactive Labs, maker of video game-like treatments for children with ADHD and autism spectrum disorder, has found a partner to help promote its digital therapeutic products in eastern Asia.
Thanks to a new strategic partnership announced this morning, Osaka, Japan-based pharmaceutical company Shionogi will take over the commercialization, marketing, clinical development and...
January 3, 2019
A small feasibility study conducted by the Children’s Hospital of Philadelphia suggests that Project: Evo, the digital medicine developed by Akili Interactive Labs that is delivered via a video game, continually engaged children with autism spectrum disorder (ASD) and reduced their ADHD symptoms, although more objective measures of cognitive control were mixed.
Nineteen children aged...
August 20, 2018
A recent small study published in Nature’s Translational Psychiatry journal observed a change in the brain networking and behavior of boys receiving a video game-based treatment for ADHD.
Conducted in Singapore, the study was conducted as part of a larger controlled investigation of boys with ADHD. It compared an intervention group of 18 participants (mean age 9 years) to a control arm of 11...